Fundraising Fox

Nuwellis

Eden Prairie, US · 3 known investors

Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings. The company focuses on treating the interconnection between heart and kidney function to improve patient outcomes and accelerate recovery.

BiotechHardwareHealthtechMedical Devices

Founders & leadership

RSRob Scott
Rob ScottinChief Financial Officer2023–2025
NJNestor Jaramillo, Jr.
Nestor Jaramillo, Jr.inPresident and Chief Executive Officer (CEO)2021–2025Nestor Jaramillo, Jr. is an independent director and former public company CEO with more than 30 years of experience in medical technology, capital markets, and operations, with background in commercialization, mergers and acquisitions, and board governance across public, private, and nonprofit organizations; he has conducted business internationally in Europe and Latin America and is fluent in English and Spanish.
BB
Brian BrownExecutive
DA
David A. RosaExecutive
CDClaudia Drayton
Claudia DraytoninExecutive
DJ
Debra J. KridnerExecutive
MW
Molly WadeExecutive
KO
Kimberly OlesonExecutive
KB
Kevin BassettExecutive
JM
Jeffrey MathiesenExecutive
WP
William PetersExecutive
JYJim Yearick
Jim YearickinVice President, Sales and Marketing2011–2014Jim Yearick has held senior leadership roles at multiple multinational medical device and healthcare companies, with experience in business development, product launches, and building global sales and marketing teams. He has also been involved with three earlier-stage medical device companies through exit transactions.

Investors · 3

Ascension VenturesSaint Louis · $10M – $20M
Kaiser Permanente VenturesSan Francisco · $2M – $5M
SV Health InvestorsBoston · $1M – $20M

Funding

SEC filings, press & company announcements

$22.3M disclosed across 13 of 17 rounds · 2012–2026

  • Undisclosed amountregistered direct offeringJul 2026 · 2 sources
    Source ↗
▶$3.8MraisedNov 2024 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Archelle Georgiou, M.D.Director
  • Mike McCormickDirector
  • Maria Rosa Costanzo, M.D.Director
  • Nestor Jaramillo, Jr.Executive Officer, Director
  • John L. ErbDirector
  • Neil P. AyotteExecutive Officer
  • Gregory WallerDirector
  • Rob ScottExecutive Officer
  • Dave Kendrick McDonaldDirector
Offering amount
$3.8M
Amount sold
$3.8M
Sales commissions
$382.9K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedSep 2024 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil P. AyotteExecutive Officer
  • Nestor Jaramillo, Jr.Executive Officer, Director
  • Rob ScottExecutive Officer
  • Dave Kendrick McDonaldDirector
  • Archelle Georgiou, M.D.Director
  • Mike McCormickDirector
  • John L. ErbDirector
  • Maria Rosa Costanzo, M.D.Director
  • Gregory WallerDirector
Sales commissions
$71.3K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedAug 2024 · 7 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Mike McCormickDirector
  • Gregory WallerDirector
  • Neil P. AyotteExecutive Officer
  • Archelle Georgiou, M.D.Director
  • Maria Rosa Costanzo, M.D.Director
  • John L. ErbDirector
  • Rob ScottExecutive Officer
  • Nestor Jaramillo, Jr.Executive Officer, Director
  • Dave Kendrick McDonaldDirector
Sales commissions
$139.3K
Placement agents
Roth Capital Partners, LLC
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedJun 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John L. ErbDirector
  • Michael Kendrick McCormickDirector
  • Nestor JaramilloExecutive Officer, Director
  • Gregory WallerDirector
  • Lynn Larson BlakeExecutive Officer
  • Jon SalvesonDirector
  • Maria Rosa CostanzoDirector
  • Neil P. AyotteExecutive Officer
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedMay 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John L. ErbExecutive Officer, Director
  • Warren S. WatsonDirector
  • Claudia DraytonExecutive Officer
  • Maria Rosa CostanzoDirector
  • Steve BrandtDirector
  • Jon SalvesonDirector
  • Gregory WallerDirector
Offering amount
$1.7M
Amount sold
$1.7M
Sales commissions
$136K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedApr 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maria Rosa CostanzoDirector
  • John L. ErbExecutive Officer, Director
  • Warren S. WatsonDirector
  • Gregory WallerDirector
  • Jon SalvesonDirector
  • Steve BrandtDirector
  • Claudia DraytonExecutive Officer
Offering amount
$2.2M
Amount sold
$2.2M
Sales commissions
$178.1K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Apr 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedMar 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory WallerDirector
  • Jon SalvesonDirector
  • Maria Rosa CostanzoDirector
  • Steve BrandtDirector
  • Claudia DraytonExecutive Officer
  • John L. ErbExecutive Officer, Director
  • Warren S. WatsonDirector
Offering amount
$1.2M
Amount sold
$1.2M
Sales commissions
$99.9K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Mar 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jon SalvesonDirector
  • Gregory WallerDirector
  • Warren S. WatsonDirector
  • Steve BrandtDirector
  • Maria Rosa CostanzoDirector
  • John L. ErbExecutive Officer, Director
  • Claudia DraytonExecutive Officer
Offering amount
$1.4M
Amount sold
$1.4M
Sales commissions
$109.2K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

NUWE Stock Slides As Nuwellis Strikes New Pediatric Dealstimothysykes.com · Aug 2026Nuwellis Highlights Aquadex Growth in Updated Presentation - TipRanks.comtipranks.com · Aug 2026Nuwellis enters co-promotion deal for cardiac monitoring device By Investing.cominvesting.com · Aug 2026Tickerontickeron.com · Aug 2026Nuwellis (NUWE) Raises Capital via Registered Direct Offering Amid Low Price-to-Sales Valuationgurufocus.com · Jul 2026Nuwellis raises $3.4 million in registered direct offering By Investing.cominvesting.com · Jul 2026

Frequently asked questions

What does Nuwellis do?
Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings. The company focuses on treating the interconnection between heart and kidney function to improve patient outcomes and accelerate recovery.
Who are Nuwellis's investors?
Nuwellis's investors include Ascension Ventures, Kaiser Permanente Ventures, SV Health Investors.
How much funding has Nuwellis raised?
Nuwellis has disclosed $22.3M raised across 13 of its 17 known rounds.
Where is Nuwellis headquartered?
Nuwellis is headquartered in Eden Prairie, US.